Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment
NCT01637194Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerTreatment